Research To Practice | Oncology Videos

Latest Episodes:

Gastrointestinal Cancers | Oncology Today with Dr Neil Love: Role of HER2-Directed Therapy in the Treatment of HER2-Expressing Gastrointestinal Cancers — Part 2 of a Special 3-Part Edition Apr 16, 2024

Show notes

Featuring an interview with Dr Kanwal Raghav, including the following topics:

Activity and tolerability of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing colorectal cancer (CRC) (0:00)
Case: A woman in her mid 50s with multiregimen-refractory metastatic CRC receives T-DXd on a clinical trial (11:19)
Case: A woman in her early 60s with advanced intrahepatic cholangiocarcinoma receives zanidatamab on a clinical trial (18:11)
Molecular pathways and mechanisms of HER2 in cancer; clinical implications and future directions for gastrointestinal cancers (20:33)
Evolving paradigm surrounding HER2 and other oncogene-addicted targets (29:32)

CME information and select publications

Chronic Lymphocytic Leukemia | Oncology Today with Dr Neil Love: Key Presentations on Chronic Lymphocytic Leukemia from Recent Major Conferences Apr 12, 2024

Show notes

Featuring perspectives from Dr Bita Fakhri, including the following topics:

Overview of select presentations from ASH 2023; recent FDA approval of lisocabtagene maraleucel (0:00)
6-year follow-up from the Phase III CLL14 trial of first-line venetoclax/obinutuzumab versus chlorambucil/obinutuzumab for chronic lymphocytic leukemia (CLL) (7:36)
Updates from ASH 2023 from the Phase III FLAIR study of minimal residual disease (MRD)-guided ibrutinib in combination with venetoclax for previously untreated CLL (13:28)
57-month follow-up from the Phase III GLOW trial of fixed-duration ibrutinib/venetoclax for previously untreated CLL (22:28)
Current clinical role of MRD testing for CLL (28:11)
Key findings from 5-year follow-up of the Phase II CAPTIVATE study for patents with CLL/small lymphocytic leukemia (SLL) with relapse after first-line fixed-duration ibrutinib/venetoclax (36:43)
6-year update from the Phase III ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for treatment-naïve CLL (41:57)
Updates from ASH 2023 for the management of relapsed/refractory CLL (54:30)
Recent updates for the management of double-refractory CLL (58:05)
Novel therapies under investigation for patients with CLL/SLL (1:10:57)
Key findings guiding the clinical management of Richter's transformation (1:13:44)
Case: A man in his early 80s with IGHV-unmutated del(17p) CLL experiences disease progression 3 years after completing second-line venetoclax-based therapy (1:22:17)

CME information and select publications

Colorectal Cancer | Arvind Dasari, MD, MS Apr 08, 2024

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer | Faculty Presentation 2: Other Considerations in the Management of CRC — Arvind Dasari, MD, MS

CME information and select publications

Colorectal Cancer | Thierry André, MD Apr 08, 2024

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer | Faculty Presentation 1: Targeted Treatment Approaches for Colorectal Cancer (CRC) — Thierry André, MD

CME information and select publications

Colorectal Cancer | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Colorectal Cancer Apr 08, 2024

Show notes

Featuring perspectives from Prof Thierry André and Dr Arvind Dasari, including the following topics:

Introduction: Year in Review on the Ground (0:00)
Treatment of HER2-Positive Colorectal Cancer (CRC) (7:50)
Immune Checkpoint Inhibitors for Microsatellite Instability-High CRC (24:12)
Other Key Issues (45:30)
Questions and Cases from the Community (52:30)

CME information and select publications

Urothelial Bladder Cancer | Thomas Powles, MBBS, MRCP, MD Apr 05, 2024

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Urothelial Bladder Cancer | Faculty Presentation 2: Metastatic Disease — Thomas Powles, MBBS, MRCP, MD

CME information and select publications

Urothelial Bladder Cancer | Shilpa Gupta, MD Apr 05, 2024

Show notes

Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Urothelial Bladder Cancer | Faculty Presentation 1: Nonmetastatic Urothelial Bladder Cancer (UBC) — Shilpa Gupta, MD

CME information and select publications

Urothelial Bladder Cancer | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Urothelial Bladder Cancer Apr 05, 2024

Show notes

Featuring perspectives from Dr Shilpa Gupta and Prof Thomas Powles, including the following topics:

Introduction: The Cancer-Immunity Cycle (0:00)
Nonmetastatic Urothelial Bladder Cancer — Dr Gupta (7:30)
Metastatic Urothelial Bladder Cancer — Prof Powles (33:06)

CME information and select publications

B7-H3-Targeted Antibody-Drug Conjugates | Oncology Today with Dr Neil Love: The Emerging Role of B7-H3-Targeted Antibody-Drug Conjugates Apr 04, 2024

Show notes

Featuring perspectives from Dr Manish Patel, including the following topics:

Insights into a comprehensive clinical research practice (0:00)
Transformation of the conduct and design of clinical trials (3:41)
Disparities and conundrums in clinical trial recruitment (10:11)
Rationale of clinical trial dosing and regulatory initiatives (15:37)
Innovation and advancements in oncology research and clinical development (18:47)
Practical considerations into patient care during a clinical trial (20:52)
Encouraging physicians to participate in oncology research (24:29)
Pharmacology of B7-H3 and role in tumor pathogenesis (31:56)
Current and future clinical development of ifinatamab deruxtecan (I-DXd) (34:11)
Available clinical data with vobramitamab duocarmazine across numerous solid tumors (1:02:44)
Early clinical data with HS-20093 for advanced solid tumors (1:06:36)

CME information and select publications

Prostate Cancer | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer Mar 28, 2024

Show notes

Featuring perspectives from Dr Andrew J Armstrong and Dr Maha Hussain, including the following topics:

Introduction: Carpool Karaoke — RTP Style (0:00)
Hormonal Therapy (13:36)
Other Treatment Approaches (36:50)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected